Stocks Health care SION
NASDAQ · Health careSionna Therapeutics, Inc. (SION)
It posted a net loss of $97.4M. In fiscal 2025 capital spending exceeded operating cash flow by $66.7M. At June 30, 2026 it held $63.3M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
Key facts about Sionna Therapeutics, Inc.
- Net worth
- Sionna Therapeutics, Inc. has a market value (market cap) of $163M at the latest share price, and shareholders' equity of $265.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $66.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 6, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Sionna Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
What Sionna Therapeutics, Inc. does
Sionna Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SION.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$75.3M | -$1.88 | -$66.7M |
| 2025 | n/a | -$61.7M | -$15.99 | -$52.8M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Sionna Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026Passive stake (5% or more) SCHEDULE 13G
- September 21, 2026Activist stake changed SCHEDULE 13D/A
- September 14, 2026
- August 10, 2026Other event 8-K
- August 6, 2026
- August 6, 2026
- June 18, 2026
- May 15, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026Passive stake changed SCHEDULE 13G/A
- May 12, 2026
Insider trades
What the people running Sionna Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $21.8M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 17, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 3,415,011 | $21.6M |
| September 17, 2026 | Ra Capital Management, L.P.Director, 10% owner | Soldindirect | 33,800 | $252.1K |
| September 17, 2026 | Cloonan MichaelPresident & CEO, Director | Received as pay | 109,025 | - |
| September 17, 2026 | Cloonan MichaelPresident & CEO, Director | Received as pay | 109,025 | - |
| September 17, 2026 | Ridloff ElenaCFO and CBO | Received as pay | 47,269 | - |
| September 17, 2026 | Ridloff ElenaCFO and CBO | Received as pay | 47,268 | - |
| September 17, 2026 | McKee CharlotteCMO and Head of R&D | Received as pay | 50,000 | - |
| September 17, 2026 | McKee CharlotteCMO and Head of R&D | Received as pay | 50,000 | - |
Who owns SION
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Tpg GP A, LLC13D, may seek influence with 2 related filers | 15.2% | February 18, 2025 |
| RA Capital Management, L.P.13D, may seek influence with 4 related filers | 14.3% | September 21, 2026 |
| Viking Global Investors LP13G, passive with 9 related filers | 7.1% | May 15, 2026 |
| Orbimed Advisors LLC13D, may seek influence with 1 related filers | 6.6% | April 20, 2026 |
| The Goldman Sachs Group, Inc.13G, passive with 1 related filers | 5.8% | November 9, 2026 |
| Enavate Sciences GP, LLC13D, may seek influence with 1 related filers | 5.6% | February 18, 2025 |
| Atlas Venture Fund XI, L.P.13D, may seek influence with 5 related filers | 5.4% | October 20, 2025 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 147 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| RA Capital Management, L.P. | 9,905,045 | 0 |
| Tpg GP A, LLC | 6,494,962 | 0 |
| Viking Global Investors LP | 3,195,181 | 0 |
| Atlas Venture Life Science Advisors, LLC | 2,995,602 | 0 |
| Orbimed Advisors LLC | 2,555,877 | -974,825 |
| Enavate Sciences GP, LLC | 2,478,030 | 0 |
| Adage Capital Partners GP, L.L.C. | 1,600,000 | +1,450,000 |
| BlackRock, Inc. | 1,474,769 | +178,902 |
| Jpmorgan Chase & Co | 1,490,508 | +25,494 |
| Jennison Associates LLC | 1,172,133 | -279,087 |
| Citadel Advisors LLC | 1,147,636 | -19,295 |
| Vanguard Capital Management LLC | 1,132,001 | +102,504 |
| State Street Corp | 1,021,534 | +265,307 |
| Perceptive Advisors LLC | 905,000 | +246,561 |
| Deerfield Management Company, L.P. | 680,916 | -289,674 |
| Siren, L.L.C. | 610,515 | +310,515 |
| Eventide Asset Management, LLC | 474,981 | -170,549 |
| Geode Capital Management, LLC | 457,145 | +67,273 |
| Baker Bros. Advisors LP | 400,000 | 0 |
| Casdin Capital, LLC | 400,000 | new |
Insiders
8 insiders reported holding 15,966,834 shares in total, about $57.6M at the last price.
| Holder | Shares |
|---|---|
| Tpg Gp A, LLC10% owner | 6,494,9626,494,962 held indirectly |
| Ra Capital Management, L.P.Director, 10% owner | 3,448,8123,448,812 held indirectly |
| Thompson Peter A.Director | 2,469,9592,469,959 held indirectly |
| Orbimed Advisors LLCDirector | 2,469,9592,469,959 held indirectly |
| Cloonan MichaelPresident & CEO, Director | 765,393 |
| Ridloff ElenaCFO and CBO | 133,069 |
| McKee CharlotteCMO and Head of R&D | 128,415 |
| Fitzpatrick JenniferCLO and Head of Program Mgmt. | 56,265 |
Questions about SION
What does Sionna Therapeutics, Inc. do?
Sionna Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as SION. Its shares trade on NASDAQ under the ticker SION.
What is Sionna Therapeutics, Inc.'s net worth?
Sionna Therapeutics, Inc. has a market value (market cap) of $163M at the latest share price, and shareholders' equity of $265.8M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Sionna Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $97.4M.
When did Sionna Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from November 9, 2026.
When is Sionna Therapeutics, Inc.'s next earnings report?
Sionna Therapeutics, Inc.'s next report was expected around November 4, 2026 and is not on file with the SEC yet.
Similar companies
Compare SION with
Follow SION
Get an email when Sionna Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Sionna Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.